BioHarvest Sciences to Host Corporate Update Call May 2 at 2:30 P.M. Eastern Time
BioHarvest Sciences to Host Corporate Update Call May 2 at 2:30 P.M. Eastern Time
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 1, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced that it will host a corporate update call on Thursday, May 2nd to discuss recently announced milestone achievements, including full year 2023 financial results, and the recent acquisition of an expanded corporate campus.
不列颠哥伦比亚省温哥华和以色列雷霍沃特--(Newsfile Corp.,2024年5月1日)——开创其专利植物合成技术平台的生物技术公司BioHarvest Sciences Inc.(CSE:BHSC)(OTCQB:CNVCF)(“BioHarvest” 或 “公司”)今天宣布,将于5月2日星期四举办企业最新情况电话会议和 讨论最近宣布的里程碑成就,包括2023年全年财务业绩以及最近对扩建的企业园区的收购。
CEO Ilan Sobel and Chairman Zaki Rakib will host the call at 2:30 p.m. Eastern time on Thursday, May 2nd, 2024, with a formal presentation providing their comments on the 2023 Financial results, on the recent acquisition of a new corporate campus, and on the proposed path for the Company to meet Nasdaq listing requirements. The shareholder update call will feature a live Q+A session. To participate, please use the following information:
首席执行官伊兰·索贝尔和董事长扎基·拉基布将于美国东部时间5月2日星期四下午 2:30 主持电话会议和,2024年,他们将发表正式演讲,对2023年财务业绩、最近收购新企业园区以及公司满足纳斯达克上市要求的拟议途径发表评论。股东更新电话会议将包括现场问答环节。要参与,请使用以下信息:
Fourth Quarter 2023 Shareholder Update Webinar
Date: Thursday, May 2, 2024
Time: 2:30 p.m. Eastern time
Zoom link:
2023 年第四季度股东最新动态网络研讨会
日期:2024 年 5 月 2 日,星期四
时间:美国东部时间下午 2:30
缩放链接:
Please join at least five minutes before the start of the call to ensure timely participation.
请在电话会议开始前至少五分钟加入,以确保及时参与。
Chairman Zaki Rakib said: "We have achieved multiple milestones over the last several months, building on our strong pace of operational execution. In preparation for future growth, we recently announced that we secured an 80,000 square ft. facility in Israel with a 50 Ton manufacturing capacity and additional space to consolidate our laboratory and office facilities under a single roof. This included 12 state-of-the-art clean rooms, which will prove instrumental as we scale our CDMO services business in the quarters to come."
董事长扎基·拉基布说:“在我们强劲的运营执行步伐的基础上,我们在过去的几个月中取得了多个里程碑。为了为未来的增长做准备,我们最近宣布,我们在以色列获得了一座占地80,000平方英尺的工厂,其制造能力为50吨,并提供了额外的空间,可以将我们的实验室和办公设施整合到一个屋檐下。其中包括12个最先进的洁净室,这将有助于我们在未来几个季度扩大CDMO服务业务。”
CEO Ilan Sobel added: "We announced yesterday our fourth quarter financial results, highlighted by an 85% increase in revenue to a record $4.5 million. We continued to strengthen our margins as well, growing them to 51% in the fourth quarter, as compared to 27% in the prior year. This financial performance, when paired with the pipeline of incremental growth drivers in our D2C Products and CDMO Services business units, positions us well in 2024 to drive continued financial momentum across our business."
首席执行官伊兰·索贝尔补充说:“我们昨天公布了第四季度财务业绩,收入增长了85%,达到创纪录的450万美元,突显了这一点。我们还继续提高利润率,第四季度利润率增长至51%,而去年同期为27%。这种财务业绩,加上我们的D2C产品和CDMO服务业务部门的增量增长动力,使我们在2024年处于有利地位,可以推动整个业务的持续财务势头。”
About BioHarvest Sciences Inc.
BioHarvest 科学公司简介
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit .
BioHarvest Sciences Inc.(CSE:BHSC)(场外交易代码:CNVCF)(FSE:8MV)是植物合成领域的领导者,利用其专利技术平台培育植物基分子,无需种植底层植物。BioHarvest正在利用其植物合成技术在两个主要垂直业务领域开发基于科学且经过临床验证的下一代治疗解决方案;作为代表寻求复杂分子的客户的合同开发和生产组织(CDMO),以及作为专有营养保健品健康和保健产品(包括膳食补充剂)的创造者。要了解更多信息,请访问。
Forward-Looking Statements
前瞻性陈述
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is no assurance that the Company will maintain or improve current financial performance, as revenues and margins are dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences. Revenue projections are estimates and there is no assurance will occur when estimated as the timing is dependent on consumer acceptance and cost stability and other factors beyond company control. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well.
本新闻稿中提供的信息可能包括基于管理层当前估计、信念、意图和预期的前瞻性陈述,并且存在许多风险和不确定性,这些风险和不确定性可能导致实际业绩与前瞻性陈述中描述的结果存在重大差异。推出新产品面临风险和不确定性,包括市场不接受该产品或无法获得销售或进口产品所需的政府批准的风险。无法保证公司会保持或改善当前的财务业绩,因为收入和利润率取决于供应链效率、投入成本稳定性、营销效率和不确定的消费者偏好等多种因素。收入预测是估计值,无法保证估算时会发生,因为时机取决于消费者的接受程度和成本稳定性以及公司无法控制的其他因素。对于CDMO服务业务部门而言,无法保证未来会有额外的合同,并提醒读者,收入的增加不一定是净收入或盈利能力的增加,因为成本也可能会增加。
Although the Company believes that it will be able to meet the requirements for Nasdaq listing, there is no assurance that a listing will occur as listing will be subject to the company being able to meet listing criteria, including being registered under US Securities Laws, a history of trading at certain price levels, and financial and share distribution requirements. Some of these requirements may be affected by matters beyond the control of the company such as conditions impacting markets generally or changes in requirements.
尽管该公司认为能够满足纳斯达克上市的要求,但无法保证上市时公司能否满足上市标准,包括根据美国证券法注册、特定价格水平的交易历史以及财务和股票分配要求。其中一些要求可能会受到公司无法控制的事项的影响,例如普遍影响市场的条件或要求的变化。
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
所有前瞻性陈述本质上都是不确定的,实际结果可能会受到许多我们无法控制的重大因素的影响。读者不应过分依赖前瞻性陈述。除了通过我们的定期管理层讨论和分析披露外,BHSC不打算更新前瞻性陈述的披露。
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
加拿大证券交易所及其监管服务提供商均不对本新闻稿的充分性或准确性承担责任。
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.
本新闻稿已由投资者关系副总裁戴夫·瑞安审查和批准,他对其内容承担责任。
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com
BioHarvest 公司联系方式
投资者关系副总裁兼董事戴夫·瑞安
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us
投资者关系联系人:
卢卡斯·A·齐默尔曼
董事总经理
MZ 集团-MZ 北美
+1 (949) 259-4987
BHSC@mzgroup.us